Sarepta Therapeutics Inc (SRPT):企業の財務・戦略的SWOT分析

◆英語タイトル:Sarepta Therapeutics Inc (SRPT) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1656
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Sarepta Therapeutics Inc (SRPT) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sarepta Therapeutics Inc (Sarepta) discovers and develops unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches to treat rare neuromuscular diseases. The company develops drugs based on its proprietary, highly-differentiated and innovative platform technology, phosphorodiamidate morpholino oligomer (PMO) chemistries. Its commercial products include, Exondys 51 is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; Golodirsen to skip exon 53 of the DMD gene. Sarepta’s key pipeline products using PMO chemistry includes Casimersen to skip exon 45 of the DMD gene. Sarepta is headquartered in Cambridge, Massachusetts, the US.

Sarepta Therapeutics Inc Key Recent Developments

Feb 27,2020 Sarepta Therapeutics announces third year of Route 79, The Duchenne Scholarship Program
Feb 26,2020 Sarepta Therapeutics announces fourth quarter and full-year 2019 financial results and recent corporate developments
Jan 13,2020 Sarepta Therapeutics appoints renowned biotech executive John C. Martin to its board of directors
Dec 13,2019 Sarepta Therapeutics announces $250 million of non-dilutive senior secured loan financing

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Sarepta Therapeutics Inc – Key Facts
Sarepta Therapeutics Inc – Key Employees
Sarepta Therapeutics Inc – Key Employee Biographies
Sarepta Therapeutics Inc – Major Products and Services
Sarepta Therapeutics Inc – History
Sarepta Therapeutics Inc – Company Statement
Sarepta Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Sarepta Therapeutics Inc – Business Description
Sarepta Therapeutics Inc – Corporate Strategy
Sarepta Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Sarepta Therapeutics Inc – Strengths
Sarepta Therapeutics Inc – Weaknesses
Sarepta Therapeutics Inc – Opportunities
Sarepta Therapeutics Inc – Threats
Sarepta Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Sarepta Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 27, 2020: Sarepta Therapeutics announces third year of Route 79, The Duchenne Scholarship Program
Feb 26, 2020: Sarepta Therapeutics announces fourth quarter and full-year 2019 financial results and recent corporate developments
Jan 13, 2020: Sarepta Therapeutics appoints renowned biotech executive John C. Martin to its board of directors
Dec 13, 2019: Sarepta Therapeutics announces $250 million of non-dilutive senior secured loan financing
Nov 15, 2019: Sarepta and StrideBio sign gene therapy development deal
Nov 07, 2019: Sarepta Therapeutics announces third quarter 2019 financial results and recent corporate developments
Aug 07, 2019: Sarepta Therapeutics announces second quarter 2019 financial results and recent corporate developments
May 23, 2019: Sarepta Therapeutics Statement on ICER draft evidence report for treatments for Duchenne Muscular Dystrophy
May 08, 2019: Sarepta Therapeutics announces first quarter 2019 financial results and recent corporate developments
Apr 15, 2019: Paragon announces its second GMP manufacturing facility and the expansion of its strategic collaboration in manufacturing design and operation with gene therapy leader Sarepta Therapeutics
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Sarepta Therapeutics Inc, Key Facts
Sarepta Therapeutics Inc, Key Employees
Sarepta Therapeutics Inc, Key Employee Biographies
Sarepta Therapeutics Inc, Major Products and Services
Sarepta Therapeutics Inc, History
Sarepta Therapeutics Inc, Other Locations
Sarepta Therapeutics Inc, Subsidiaries
Sarepta Therapeutics Inc, Key Competitors
Sarepta Therapeutics Inc, Ratios based on current share price
Sarepta Therapeutics Inc, Annual Ratios
Sarepta Therapeutics Inc, Annual Ratios (Cont...1)
Sarepta Therapeutics Inc, Interim Ratios
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Sarepta Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Sarepta Therapeutics Inc, Performance Chart (2015 - 2019)
Sarepta Therapeutics Inc, Ratio Charts
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sarepta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Sarepta Therapeutics Inc (SRPT):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ramsay Health Care Limited:企業の戦略・SWOT・財務情報
    Ramsay Health Care Limited - Strategy, SWOT and Corporate Finance Report Summary Ramsay Health Care Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Nostrum Oil & Gas PLC (NOG):石油・ガス:M&Aディール及び事業提携情報
    Summary Nostrum Oil & Gas PLC (Nostrum) is an independent oil and gas company. It produces, develops, and explores for oil and gas in the pre-Caspian Basin. The company produces crude oil, stabilized liquid condensate, LPG and dry gas. Nostrum has commercial hydrocarbon reserves in the Ardatovski, L …
  • Ultrapar Participacoes S.A.:企業の戦略・SWOT・財務分析
    Ultrapar Participacoes S.A. - Strategy, SWOT and Corporate Finance Report Summary Ultrapar Participacoes S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Nativis Inc-医療機器分野:企業M&A・提携分析
    Summary Nativis Inc (Nativis) is a clinical stage bio-electronics company. Its portfolio of pipeline candidates which are under development for various therapeutic areas include recurrent glioblastoma, brain metastisis, pain, rheumatoid arthritis, lung cancer and melanoma. The company’s lead product …
  • InVivo Therapeutics Corp:企業の製品パイプライン分析2018
    Summary InVivo Therapeutics Corp (InVivo), a subsidiary of InVivo Therapeutics Holdings Corp, is a medical device company that offers therapeutic products. The company develops and commercializes groundbreaking treatments for spinal cord injuries. Its products include biocompatible neuro spinal scaf …
  • Inform Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Inform Diagnostics Inc(Inform Diagnostics) formerly known as Miraca Life Sciences, a subsidiary of Miraca Holdings Inc, is an anatomic pathology laboratory that offers diagnostic services. The laboratory provides services in the areas of breast health, dermatology, gastroenterology, hematolo …
  • Xenon Pharmaceuticals Inc (XENE):製薬・医療:M&Aディール及び事業提携情報
    Summary Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc, is a biopharmaceutical company that discovers and develops therapeutics for patients suffering with neurological disorders. The company's pipeline products include XEN1101, XEN901, XEN007 and GDC-0310. It discovers various valid …
  • Indra Sistemas SA (IDR):企業の財務・戦略的SWOT分析
    Indra Sistemas SA (IDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • AB Science SA (AB)-製薬・医療分野:企業M&A・提携分析
    Summary AB Science SA (ABS) is a pharmaceutical company that discovers, develops and commercializes tyrosine kinase inhibitor. The company concentrates its research on inflammatory diseases, cancers and central nervous system diseases in human and veterinary medicine. Its masitinib is an orally admi …
  • Aileron Therapeutics Inc (ALRN):製薬・医療:M&Aディール及び事業提携情報
    Summary Aileron Therapeutics Inc (Aileron Therapeutics) is a biopharmaceutical company that discovers, develops, and commercializes novel class of therapeutics. The company provides products such as stapled peptide drugs. Its stapled peptides penetrate cells throughout the body and modulate intracel …
  • Nippon Shokubai Co Ltd (4114):企業の財務・戦略的SWOT分析
    Nippon Shokubai Co Ltd (4114) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • CIC Private Banking:企業の戦略・SWOT・財務情報
    CIC Private Banking - Strategy, SWOT and Corporate Finance Report Summary CIC Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Imprimis Pharmaceuticals Inc (IMMY):製薬・医療:M&Aディール及び事業提携情報
    Summary Imprimis Pharmaceuticals Inc (Imprimis), formerly Transdel Pharmaceuticals Inc., focuses on the development and commercialization of proprietary drug formulations in the therapeutic areas of urology and ophthalmology. The company by utilizing its SSP Technology develops injectable Dropless T …
  • Reach Subsea ASA (REACH):石油・ガス:M&Aディール及び事業提携情報
    Summary Reach Subsea ASA (Reach) provides engineering consultancy services and advanced remotely-operated underwater vessels (ROV) to the oil industry. The company also offers inspection, maintenance and repair, survey, construction support and decommissioning services. Reach offers multi-support ve …
  • Telekom Austria AG:企業の戦略・SWOT・財務情報
    Telekom Austria AG - Strategy, SWOT and Corporate Finance Report Summary Telekom Austria AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • PT ANTAM (Persero) Tbk:企業の戦略・SWOT・財務情報
    PT ANTAM (Persero) Tbk - Strategy, SWOT and Corporate Finance Report Summary PT ANTAM (Persero) Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • SEAKR Engineering, Inc.:企業の戦略・SWOT・財務情報
    SEAKR Engineering, Inc. - Strategy, SWOT and Corporate Finance Report Summary SEAKR Engineering, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Biomatrica Inc:医療機器:M&Aディール及び事業提携情報
    Summary Biomatrica Inc (Biomatrica) is a developer, manufacturer, and supplier of stability technologies preserve biological materials. The company offers DNA, RNA, proteins, cells, and entire assays for diagnostics, research, forensics, biobanks, and sustainability applications. Its products includ …
  • Avantis Medical Systems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Avantis Medical Systems Inc (AMS) is a medical device company that provides visualization technology solutions. The company uses its technology platform and software analysis for the screening and early detection of cancer. It offers products such as single camera colonoscopy devices and thi …
  • Perdana Petroleum Bhd (PERDANA):企業の財務・戦略的SWOT分析
    Perdana Petroleum Bhd (PERDANA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆